Navigation Links
Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
Date:4/14/2011

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Competitor Analysis: Targeted Therapy of Diabetes

http://www.reportlinker.com/p0483024/Competitor-Analysis-Targeted-Therapy-of-Diabetes.html

Product description

The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:

-Drug Codes,

-Target / Mechanism of Action,

-Class of Compound,

-Company,

-Product Category,

-Indication,

-R&D Stage and

-additional comments with a hyperlink leading to the source of information. 

Insulin

Rec Human Insulin for Injection (2nd Generation)

Biosimilar Rec Human Insulin for Injection (2nd Generation) in

Regulated Markets

Rhu Insulin (2nd Generation) in Off-Patent Countries: China

Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia

Rhu Insulin (2nd Generation) in Off-Patent Countries: India

Rhu Insulin (2nd Generation) in Off-Patent Countries: Others

Modern Insulin Analogs (3rd Generation) for Injection

Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets

Tailored and Novel Insulin Analogs (4th Generation) for

Injection

Human Insulin with Drug Delivery for Injection

Other Long-Acting Insulin for Injection

Transgenic Human Insulin for Injection

Insulin/GLP-1 Combination Products

Inhaled Insulin

Oral Insulin

Transdermal Insulin

Others

PPAR Agonists

PPAR alpha A<gonists

PPAR gamma Agonists / Insulin Sensitizer

PPAR alpha and gamma Agonists

PPAR delta Agonists

PPAR delta and gamma Agonists

PPAR alpha and delta Agonists

PPAR pan Agonists (alpha, gamma and delta)

Unspecified PPAR Agonists

Dipeptidyl peptidase-IV (DPP-IV) Inhibitors

GLP-1 Receptor Agonists

GLP-1 Analogs with Daily SC Injections

GLP-1 Analogs with Once Weekly SC Injections

GLP-1 Analogs with Bi-Weekly or Monthly SC Injections

Other GLP-1 Analogs for SC Injections

GLP-1 Analogs in Drug Delivery Formulations/Devices for

Parenteral Administration

GLP-1 Analogs in Drug Delivery Formulations for Oral

Administration

Oral Small Molecule GLP-1 Receptor Agonists

Dual Target GLP-1 Receptor Agonists / Combination Products

GLP-1 Analogs in Other, Non-Diabetes Indications

Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors

11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors

Glucokinase Activators (GKA)

Other Emerging Diabetes Drugs

Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists

Sirtuin (SIRT) Activators

Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors

Glucagon Receptor (GCGR) Antagonists

Glucocorticoid Receptor (GCGR) Antagonists

Novel Insulin Sensitizers

G-Protein Coupled Receptor 119 (GPR119) Agonists

Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists

Other Glucometabolic Approaches

Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors

Other Metabolic Approaches

FGF-21-Receptor Agonists

Anti-Inflammatory Approaches

Induction of Immune Tolerance

Pancreatic Beta Cell Protection & Regeneration

Pancreatic Islet Cell Transplantation

Various Antidiabetic Approaches

To order this report:

: Competitor Analysis: Targeted Therapy of Diabetes

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds China Bio-breeding Industry Report, 2010
2. Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other
3. Reportlinker Adds Biomarker Partnering Terms and Agreements
4. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
5. Reportlinker Adds Industrial Biotechnology China News 1103
6. Reportlinker Adds DNA Sequencing - Technologies, Markets and Companies
7. Reportlinker Adds Cytogenetics - Technologies, Markets and Companies
8. Reportlinker Adds Animal Biotechnology - Technologies, Markets and Companies
9. Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies
10. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
11. Reportlinker Adds Molecular Diagnostics Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):